TABLE 2.
Median signal strengths for detected HPV infections and CIN lesions in samples with one or all four HPV assays returning a positive result
| No. of positive HPV test results | Median (IQR) signal strength for detected HPV infections |
No. of detected histologically confirmed CIN lesionsa (% of total) |
||||
|---|---|---|---|---|---|---|
| HC2 | cobas | Aptima | ≤CIN1b | ≥CIN2 | ≥CIN3 | |
| Primary screening at 30–65 yr | ||||||
| 1 | 2.3 (1.5–8.5) | 39.2 (38.3–39.8) | 1.9 (0.9–6.5) | 33/100 (33.0) | 0/50 (0) | 0/38 (0) |
| 4 | 53.9 (11.5–200.2) | 28.2 (25.7–31.3) | 10.8 (8.4–11.8) | 34/100 (34.0) | 42/50 (84.0) | 31/38 (81.6) |
| Referral population | ||||||
| 1 | 5.2 (1.7–24.4) | 38.9 (37.7–39.3) | 2.1 (0.6–5.5) | 35/176 (19.9) | 3/129 (2.3) | 3/89 (3.4) |
| 4 | 147.9 (32.8–512.1) | 26.8 (23.8–29.6) | 11.1 (9.8–14.8) | 95/176 (54.0) | 105/129 (81.4) | 72/89 (80.9) |
a
Among lesions detected by at least one HPV assay. One woman with all four HPV assays returning negative test results had CIN3. Recalculated as detection per 100 women undergoing HPV testing, the proportions of ≤CIN1 were 3.5% (100/2,859) in the screening population and 19.9% (176/885) in the referral population. The proportions of ≥CIN2 were 1.7% (50/2,859) and 14.6% (129/885), respectively, and the proportions of ≥CIN3 were 1.3% (38/2,859) and 10.1% (89/885), respectively.
b
Includes normal histology and histologically confirmed CIN1.